Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

EGFR/HER2 inhibitor TAS2940

An orally bioavailable, small molecule inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with potential antineoplastic activity. Upon oral administration, EGFR/HER2 inhibitor TAS2940 targets, binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	TA-S2940 TAS 2940 TAS2940

EGFR/HER2 inhibitor TAS2940

Search NCI's Drug Dictionary